The study end points were overall survival and recurrence.
The study was approved by the Institutional Review Board of MD Anderson Cancer Center.0.05 in Caucasian population in 10 GWAS-identified CRC susceptibility regions were selected and genotyped with Taqman assay using the ABI 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA) (Supplementary Table 1 is available at test or Fisher's exact test was applied to compare the distribution of selected demographic and clinical variables by recurrence and vital status.
All the participants were followed up until February 2010.
Due to the limited sample size of patients with stage I and stage IV patients and the marked differences in outcome and end points by different stages and treatment, we focused on stage II and stage III patients receiving surgery and 5-FU-based adjuvant chemotherapy for further analyses.
shows the selected demographic and clinical characteristics of 285 patients who received surgery and 5-FU-based adjuvant chemotherapy.The Cox proportional hazard model was used to assess the effect of individual SNPs on overall survival and recurrence-free survival, defined as the time from the date of surgical resection to the date of death/recurrence or last follow-up.Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated by fitting the Cox model while adjusting for age, gender, race, tumor location and histology grade.Three SNPs: rs10749971 (11q23.1), rs961253 (20p12.3) and rs355527 (20p12.3) in two regions were significantly associated with recurrence for patients with stage III disease.Five SNPs: rs961253 (20p12.3), rs355527 (20p12.3), rs4464148 (18q21.1), rs6983267 (8q24.21) and rs10505477 (8q24.21) in three regions were significantly associated with survival for patients with stage III disease.